Curriculum Vitae
Personal Information
Name: Xiaojiang Cui, PhD
Research interests: breast cancer metastasis, targeted therapy, therapeutic resistance, cancer stem cells
in breast cancer progression
Academic Affiliations
Department of Surgery
Department of Obstetrics and Gynecology
Women’s Cancer Program
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Contact Information
8700 Beverly Blvd
West Tower, Suite 290
Los Angeles, CA 90048
Tel: 310-423-7437 (office), 310-423-7618 (laboratory), Fax: 310-423-9537
Email: [email protected]
Education
1986-1990
1995-1999
East China University of Science and Technology, Shanghai, China, B.S.,
Biochemistry
the University of Texas at Austin, Austin, TX, Ph.D., Molecular Biology
Research and Teaching Experience
1990-1995
Research Scientist, Institute of Microbiology, the Chinese Academy of
Sciences,
Beijing, China
1995-1999
Teaching Assistant, the University of Texas at Austin, Austin, TX
2000-2003
Postdoctoral fellow, Breast Center, Department of Medicine, Baylor College
of
Medicine, Houston, TX
2003-2007
Instructor, Breast Center, Department of Medicine, Baylor College of
Medicine,
Houston, TX
2007-2011
Assistant Professor, Department of Molecular Oncology, John Wayne Cancer
Institute,
Saint John’s Health Center, Santa Monica, CA
2007-2011
Director, Translational Breast Research, John Wayne Cancer Institute, Saint
John’s
Health Center, Santa Monica, CA
2010-2011
Member, Saint John’s Health Center Cancer Committee, Santa Monica, CA
2010-2011
Maria Lim McClay Research Scholar, John Wayne Cancer Institute, Santa Monica, CA
2011-present Faculty Scientist II, Department of Surgery, Department of Obstetrics
and
Gynecology, Women’s Cancer Program, Samuel Oschin Comprehensive
Cancer
Institute, Cedars-Sinai Medical Center, Los Angeles, CA
2012-present Associate Professor, Department of Surgery, Department of Obstetrics
and
Gynecology, Women’s Cancer Program, Samuel Oschin Comprehensive
Cancer
Institute, Cedars-Sinai Medical Center, Los Angeles, CA
1
2013-present
College
Visiting Professor, Breast Surgery
Hospital, Beijing, China
Department,
Peking
Union
Medical
Awards
1988 Honor Student Award (one of five recipients in the university), East China University
of
Science and Technology, Shanghai, China
1990
Outstanding University Graduate Award, East China University of Science and
Technology,
Shanghai, China
1996 Tuition Fellowship Award, the University of Texas at Austin, Austin, TX
1997 Tuition Fellowship Award, the University of Texas at Austin, Austin, TX
1998 Professional Development Award, the University of Texas at Austin, Austin, TX
1999 The American Society of Plant Biologists annual meeting Travel Grant Award
2001 U.S. Department of Defense Breast Cancer Research Program Postdoctoral Training Award
2003 First Place Award of the abstract contest for the 1st Annual Dan L. Duncan Cancer
Center
Retreat and Symposium, Baylor College of Medicine and affiliated hospitals,
Houston, TX
2004 Career Development Award, NIH/NCI Breast Cancer SPORE, Baylor College of
Medicine,
Houston, TX
2006
Presentation Award for the 2nd Annual Breast Program Retreat, Dan L. Duncan Cancer
Center,
Baylor College of Medicine and affiliated hospitals, Houston, TX
2009 Abstract Merit Award (fellow Partha Ray, MD), American Society of Clinical
Oncology
Annual Meeting, Orlando, FL
2009
Abstract Merit Award (fellow Partha Ray, MD), American Society of Clinical Oncology
Breast
Cancer Symposium, San Francisco, CA
2010
Abstract Merit Award (fellow Christopher Moran, MD), American Society of
Clinical
Oncology Gastrointestinal Cancers Symposium, San Francisco, CA
2011 Best Clinical Research Poster Award (fellow Christopher Moran, MD), Society of
Surgical
Oncology Annual Meeting, San Antonio, TX
Professional Societies
2000-2004
Associate member of the American Association for Cancer Research
2000-2006
Associate member of the Endocrine Society
2004-present Active member of the American Association for Cancer Research
2006-present Active member of the Endocrine Society
Journal Reviewer
Annals of Surgical Oncology, Antioxidants & Redox Signaling, BMC Cancer, Breast Cancer
Research and Treatment, Cancer Biology & Therapy, Cancer Chemotherapy and Pharmacology,
Cancer Letters, Cancer Research, Cell Proliferation, Clinical Cancer Research, Current Molecular
Medicine, Free Radical Biology and Medicine, FEBS Letters, Gynecologic Oncology, Histology and
Histopathology, International Journal of Biomedical Science, International Journal of Biological
Sciences, Journal of Cellular and Molecular Medicine, Journal of Experimental & Clinical Cancer
Research, Molecular Cancer Therapeutics, Molecular Carcinogenesis, Molecular and Cellular
Endocrinology, Tumor Biology
International examiner for PhD dissertation, Monash University, Australia
2
Editorial Work
Guest editor, journal Antioxidants & Redox Signaling (ISSN 1523-0864), special issue on Cell
Growth and Metastasis, 2011
Reviewing editor, journal Antioxidants & Redox Signaling
Editorial board member, Journal of Analytical Oncology (ISSN 1927-7229)
Grant Review
 Ad Hoc reviewer for Breast Cancer Campaign, UK, 2004.
 Ad Hoc reviewer for the Health Research Board, Ireland, 2007.
 Member, PDF-Basic 6-Tumor Progression Review Panel, Susan G. Komen for the Cure, 2011.
 Member, Training-Pathobiology (TRN-PBY) peer review panel, Breast Cancer Research
Program (BCRP), Department of Defense Congressionally Directed Medical Research
Programs (CDMRP), 2011.
 Member, Investigator Initiated Research (IIR) Novel Therapeutics and Resistance – Targeted
therapies for Triple-negative Breast Cancer Pre-application Peer Review Committee, Susan G.
Komen for the Cure, 2011.
 Member, Training 2-Pathobiology (TRN2-PBY) peer review panel, Breast Cancer Research
Program (BCRP), Department of Defense Congressionally Directed Medical Research
Programs (CDMRP), 2012.
 Member, Training-Pathobiology (TRN-PBY) peer review panel, Breast Cancer Research
Program (BCRP), Department of Defense Congressionally Directed Medical Research
Programs (CDMRP), 2013.
 Member, Generic Cancer Panel (Investigator Initiated Research Projects and Innovative,
Developmental or Exploratory Activities (IDEA) projects), the New York Stem Cell
(NYSTEM) Science Program, 2013.
Mentoring of Postdoctoral and Clinical Fellows
Partha Ray (MD), University of Illinois at Urbana-Champaign
Christopher Moran (MD), Oregon Health Science Center
Jinghua Wang (PhD), John Wayne Cancer Institute
Ying Qu (MD, PhD), Ruijin Hospital, Shanghai Second Medical University, China
Sanjay Bagaria (MD), Mayo Clinic Jacksonville
Bingchen Han (PhD), Cedars-Sinai Medical Center, current
Yanli Jin (MD, PhD), Cedars-Sinai Medical Center, current
Li Luo (MD, PhD), Cedars-Sinai Medical Center, current
Alexandra Gangi (MD), resident, Cedars-Sinai Medical Center, current
Tilley Jenkins Vogel (MD), Cedars-Sinai Medical Center, current
Invited External Lectures and Talks
1. Annual Educational Evening, John Wayne Cancer Institute Auxiliary, Skirball Cultural Center,
Los Angeles, CA, 2/25/2008.
2. Coffee Break Show, CityTV (Santa Monica, channel 16) and LA 36 (Los Angeles, channel 36),
City Hall, Santa Monica, CA, 3/26/2008.
3. National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy
of Medical Sciences and Peking Union Medical College, Beijing, China, 4/29/2008.
3
4. State Key Laboratory of Bioreactor Engineering, School of Bioengineering, East China
University of Science and Technology, Shanghai, China, 5/4/2008.
5. BIT’s 3rd Annual World Cancer Congress -- Breast Cancer Conference, Shanghai, China, 4/2527/2010.
6. Breast Cancer Forum, Avon Foundation for Women, New York, NY, 3/1-2/2011.
7. The Saint John’s Health Center Foundation Board of Trustees annual “Chautauqua” retreat, the
20th Anniversary of the John Wayne Cancer Institute (JWCI) at Saint John’s, Ojai, CA, 4/23/2011.
8. University of Pittsburgh Cancer Institute, Magee Womens Research Institute, Pittsburgh, PA,
4/25/2011.
9. The Second Affiliated Hospital, Chongqing Medical School, Chongqing, China, 10/2011.
10. Western University of Health Sciences, College of Pharmacy, Pomona, CA, 11/13/2012.
11. Cancer Biology Program, Mayo Clinic, Jacksonville, Florida, 5/3/2013.
12. 2nd International Conference on Translational and Personalized Medicine, Chicago, IL, 8/57/2013.
13. 4th Annual World Congress of Molecular & Cell Biology, Tumor Invasion and Metastasis
session chair, Dalian, China, 4/25-28/2014.
Patent Applications
1. US patent, Methods for Diagnosis, Prognosis and Treatment of Primary and Metastatic
Basal-like Breast Cancer and other Cancer Types, US Application No. 12/852,453, 8/6/2010.
2. US patent, FOXC1 antibodies and methods of their use, US Application No. 13/366,170,
2/3/2012.
3. Provisional application for US patent, Ovarian Cancer Gene Signature to Predict Outcome
and Identify Therapeutic Targets. 8/28/2012
Publications
1. Huang W, Cui X, Peng X. Advances in plant anti-bacteria genetic engineering. Biotechnol
Prog 13:17-19, 1993.
2. Cui X, Peng X, Zhou X, Mang K. Molecular analysis of transgenic potato expressing three
virus coat protein genes. Chin Sci Bull 39:1992-1995, 1994.
3. Cui X, Peng X. Advances of plant genetic engineering in anti-microbial pathogens.
Biodiversity Sci 2:96-102, 1994.
4. Cui X, Peng X, Shen Y, Mang K. Cloning and sequencing of PLRV coat protein gene and
construction of vectors for transgenic potato resistant to co-infection of PVY, PVX and PLRV.
Chin J Biotechnol 10:185-189, 1994.
5. Cui X, Peng X. Status and prospect of transgenic potato in China. Biodiversity Sci 2:72S-74S,
1994.
6. Cui X, Huang W, Liu Z, Peng X, Mang K. Expression of T7 lysozyme and its fusion proteins
in Escherichia coli. Chin J Virol 10:178-183, 1994.
7. Song Y, Li C, Hou L, Zhang L, Ma Q, Peng X, Cui X, Zhou X, Wang H, Mang K.
Construction of Plant Expression Vectors and Identification of Transgenic Potato Plants. J
Integr Plant Biol 36:842-848, 1994.
8. Huang W, Cui X, Tian Y, Lin M, Peng X. Construction of the vector for transgenic plants
resistant to bacterial infection. Acta Microbiologica Sinica 34:261-265, 1994.
4
9. Huang W, Cui X, Lin M, Peng X. Advances in the study of mycoplasma like organism.
Microbiology 21:37-40, 1994.
10. Cui X, Liu Z, Tian Y, Peng X. Advances in the antibacterial peptide research and application
prospect. Biochem Biophys Prog 22:5-8, 1995.
11. Xie A, Cui X, Song Y. Cloning and Sequencing of PHBb and PHBc in Alcaligenes eutrophus
H16. J Integr Plant Biol 37:581-588, 1995.
12. Xiang Y, Yang L, Zhou X, Cui X, Peng X. Engineering resistance to PVY in transgenic
tobacco expressing the PVY coat protein gene. Chin J Virol 11:158-162, 1995.
13. Zhang H, Peng X, Song Y, Li T, Meng Q, Liu C, Cui X. Resistance to mixed PVY and PLRV
infection in potato cultivars expressing dual PVY and PLRV coat protein genes. J Integr Plant
Biol 39:236-240, 1997.
14. Kimura S, Laosinchai W, Itoh T, Cui X, Linder CR, Brown RM. Immunogold labeling of
rosette terminal cellulose-synthesizing complexes in the vascular plant vigna angularis. Plant
Cell 11:2075-2086, 1999.
15. Cui X, Brown RM. Molecular cloning of a phospholipase D gene from cotton fibers. Plant
Physiol. 120:PGR99-119, 1999.
16. Laosinchai W, Cui X, Brown RM. A full length cDNA of cotton cellulose synthase has high
homology with the arabidopsis RSW1 gene and the cotton CelA1 gene. Plant Physiol.
122:PGR00-002, 2000.
17. Cui X, Shin H, Laosinchai W, Amano Y, Brown RM. A putative plant homolog of the yeast 1,3-glucan synthase subunit FKS1 from cotton fibers. Planta 213:223-230, 2001.
18. Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor,
and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7:4429S-4435S,
2001.
19. Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore AP, Streuli CH, Oesterreich S, Hadsell
DL. New mechanisms of signal transduction inhibitor action: Receptor tyrosine kinase downregulation and blockade of signal transactivation. Clin Cancer Res 9:516S-523S, 2003.
20. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J,
Lee AV. Estrogen mediated E-cadherin downregulation in human breast cancer cells. Cancer
Res 63:5203-5208, 2003.
21. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills BG, Lee AV. IGF-I inhibits progesterone
receptor expression in breast cancer cells via the PI3K/Akt/mTOR pathway: Progesterone
receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol
17:575-588, 2003.
22. Cui X, Lazard Z, Zhang P, Hopp, Lee AV. Progesterone cross-talks with insulin-like growth
factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene
22:6937-6941, 2003.
23. Nakashima J, Laosinchai W, Cui X, Brown RM. New Insight into the Mechanism of Cellulose
and Callose Biosynthesis: Proteases Regulate Callose Biosynthesis upon Wounding. Cellulose
10:369-389, 2003.
24. Cui X, Lee AV. Regulatory nodes that integrate and coordinate signaling as potential targets
for breast cancer therapy. Clin Cancer Res 10:396S-401S, 2004.
25. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. The biology of progesterone loss in breast
cancer and its implications for endocrine therapy. J Clin Oncol 23:7721-7735, 2005.
26. Cui X. Analysis of target gene transcription. In: Peng X, ed. Practical Methods in Plant
Molecular Biology. Beijing, Chemical Industry Press; 282-291, 2005.
5
27. Kim H-J, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with HER-2
overexpression in estrogen receptor positive breast cancer. Clin Cancer Res 12:1013s-1018s,
2006.
28. Lee AV, Weiss H, Cui X, Osborne CK, Arpino G, Schiff R. In reply: Progesterone receptor in
estrogen receptor-positive breast cancer: the association between HER-2 and lymph node
involvement is age related. J Clin Oncol 24:2595-2597, 2006.
29. Cui X, Kim H-J, Kuiatse I, Lee AV. Epidermal Growth Factor Induces Insulin Receptor
Substrate-2 in Breast Cancer Cells via JNK/AP-1 Signaling to Regulate Cell Migration.
Cancer Res 66:5304-5313, 2006.
30. Dearth RK+, Cui X+ (+, co-first author), Kim HJ, Kuiatse I, Lawrence NA, Zhang X, Divisova
J, Britton OL, Mohsin S, Allred DC, Hadsell DL, Lee AV. Mammary tumorigenesis and
metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell
Biol 26:9302-9314, 2006.
31. Kim HJ, Litzenburger BC, Cui X, Delgado DA, Grabiner BC, Lin X, Lewis MT, Gottardis
MM, Wong TW, Attar RM, Carboni J, Lee AV. Constitutively active IGF-IR causes
transformation and xenograft growth of immortalized mammary epithelial cells, and is
accompanied by an epithelial to mesenchymal transition mediated by NF-kappaB and Snail.
Mol Cell Biol 27:3165-3175, 2007.
32. Dearth RK, Cui X, Kim HJ, Hadsell D, Lee AV. Oncogenic transformation by the signaling
adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6:705-713., 2007.
33. Glaros S, Chinni SR, Cui X, Lee AV, Reddy KB. Isoform specific silencing of Akt-3 reduces
cell motility and invasion in breast tumor cells. Int J Cancer, 2008.
34. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor
receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 13:3273-3287,
2008.
35. Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D. Progesterone receptor-B regulation of IGF
stimulated cell migration in breast cancer cells via insulin receptor substrate-2 (IRS-2). Mol
Cancer Res 6:1491-1498, 2008.
36. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow
G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. Expression of
autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and
metastases. Cancer Cell 15:539-550, 2009.
37. Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X. Wang J, Kuiatse I, Lee AV, Pan J,
Giuliano A, Cui X. Wang J, Kuiatse I, Lee AV, Pan J, Giuliano A, Cui X. Sustained c-JunNH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of
breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer
Res 8:266-277, 2010 (Highlights of the Issue).
38. Qu Y, Wang J, Liu B, Giuliano A, Barsoum J, Cui X. Elesclomol, counteracted by Akt survival
signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells. Breast
Cancer Res Treat 121:311-321, 2010.
39. Ray PS, Wang J, Qu Y, Shin-Sim M, Shamonki J, Bagaria SP, Ye X, Liu B, Elashoff D, Hoon
DSB, Giuliano AE, Cui X. FOXC1 is a potential prognostic biomarker with functional
significance in basal-like breast cancer. Cancer Res 70:3870-3876, 2010 (Cover of the Issue).
40. Qu Y, Wang J, Ray PS, Guo H, Huang J, Shin-Sim M, Bukoye BA, Liu B, Lee AV, Lin X,
Huang P, Martens JW, Giuliano AE, Zhang N, Cheng NH, Cui X. Thioredoxin-like 2 regulates
6
human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. J Clin
Invest 121:212-225, 2011 (Highlights of the Issue).
41. Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, Shamonki J, Martino S, Cui X+
(+, co-corresponding author), Giuliano AE. Prognostic value of basal phenotype in HER2overexpressing breast cancer. Ann Surg Oncol, 19:935-940, 2012.
42. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The insulin-like growth factor pathway
regulates estrogen receptor alpha through a S6K1-dependent mechanism in breast cancer cells.
Mol Endocrinol 25:516-528, 2011 (Translational highlights in J Clin Endocrinol Metab 96:872,
2011).
43. Ray PS, Bagaria SP, Wang J, Shamonki J, Ye X, Sim MS, Steen S, Qu Y, Cui X+ (+, cocorresponding author), Giuliano AE. Basal-like breast cancer defined by FOXC1 expression
offers superior prognostic value: a retrospective immunohistochemical study. Ann Surg Oncol
18:3839-3847, 2011.
44. Cheng N-H, Zhang W, Chen W-Q, Jin J, Cui X, Butte NF, Chan L, Hirschi KD. A mammalian
monothiol glutaredoxin, Grx3, is critical for cell cycle progression during embryogenesis.
FEBS J 278:2525-2539, 2011.
45. Han B, Yan J, Cui X. Biology of basal-like breast cancer. In: Schatten H, ed. Cell and
Molecular Biology of Breast Cancer. Humana Press (Springer Science+Business Media LLC),
2013.
46. Cui X. Reactive oxygen species: the Achilles Heel of cancer cells? Antioxid Redox Signal,
16:1212-1214, 2012 (Forum Editorial).
47. Wang J, Qu Y, Ray PS, Sim MS, Zhou XZ, Lu KP, Liu B, Lee AV, Lin X, Bagaria SP,
Giuliano AE, Cui X. FOXC1 orchestrates basal-like breast cancer cell functions by potentiating
NF-B signaling. Oncogene 31:4798-4802, 2012.
48. Wang N, Cui X, Sun Z. The Molecular mechanism of ulinastatin as an inhibitor to the invasion
and metastasis of human breast cancer cells. Chongqing Medicine 41:3023-3025, 2012.
49. Bagaria1 SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X, Giuliano AE. Personalizing breast
cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg (in press), 2013.
50. Qu Y, Ray PS, Li J, Cai Q, Bagaria SP, Moran C, Sim MS, Zhang J, Turner RR, Zhu Z, Cui X,
Liu B. High levels of sFRP1 correlate with poor prognosis and promote tumorigenesis in
gastric cancer. Eur J Cancer (Epub ahead of print, Aug 5), 2013.
51. Chung A, Cui X, Audeh W, Giuliano A. Current status of anti-her2 therapies: predicting and
overcoming Trastuzamab resistance. Clin Breast Cancer 13:223-232, 2013.
52. Wang L, Hou Y, Sun Y, Tang X, Hu P, Yang J, Zeng Z, Yang G, Cui X, Liu M. c-Ski activates
cancer-associated fibroblasts to regulate breast cancer cell invasion. Mol Oncol (in press),
2013.
53. Jin Y, Han B, Wiedemeyer R, Orsulic S, Bose S, Karlan BY, Giuliano AE, Cui X. FOXC1 is a
critical mediator of EGFR function in cancer cells. J Clin Invest (submitted), 2013.
54. Cheng N, Qu Y, Cui X. Role of glutaredoxins in cancer development and metastasis. In: Stone
B, ed. Free Radicals: The Role of Antioxidants and Pro-oxidants in Cancer Development. Nova
Science Publishers, 2013.
55. Cheon D-J, Tong, Y, Sim M, Berel D, Cui X, Lester J, Tighiouart M, Walts, AE, Karlan B,
Orsulic S. A collagen-remodeling gene signature regulated by TGFβ signaling is associated
with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (revision under
review), 2013.
7
56. Qu Y, Zhou C, Zhang J, Cai Q, Li J, Du T, Zhu Z, Cui X, Liu B. Metastasis suppressor SOX11
is an independent prognostic factor for improved survival in gastric cancer. Int J Oncol
(submitted), 2013.
57. Three additional manuscripts in preparation.
Meeting Presentations (unpublished)
1. LaPara KS, Cui X, Lee AV, Sachdev D, Yee D. Insulin-like growth factor I (IGF-I) does not
stimulate growth in human breast cancer cells with constitutive activation of Akt3. The
Endocrine Society 86th annual meeting, P3-176, 2004.
2. Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D. IRS-2 mediates IGF-I induced cell motility in
breast cancer cells. The Endocrine Society 86th annual meeting, P1-122, 2004.
3. Hadsell DL, Divisova J, Cui X, Lawrence NS, Lee AV. Mammary gland-specific
overexpression of insulin receptor substrate-1 and -2 has minimal impact on downstream kinase
activity and does not affect mammary gland involution. The Endocrine Society 86th annual
meeting, P3-37, 2004.
Funding Support
Previous













U.S. Department of Defense Breast Cancer Research Program Postdoctoral Fellowship
Award DAMD17-01-1-0133, $150,000; 7/1/2001--6/30/2004.
NIH/NCI SPORE P50 CA58183 Career Development Award, $160,000; 7/1/2004-6/30/2006.
Susan G. Komen Breast Cancer Foundation Research Award BCTR0601346, $249,947;
5/1/06--4/30/09.
Green Foundation Research Award, $32,000; 8/01/2008--7/31/2009.
Del E. Webb Foundation Research Award, $50,000; 11/01/2009--10/31/2010.
George I. Adler and Carole Zumbro Breast Cancer Research Award, $250,000; 1/1/2009-12/31/2010.
Avon Foundation Research Award, 02-2008-081, $300,000; 1/1/2009--12/31/2010.
Associates for Breast & Prostate Cancer Studies Research Award, $104,100; 9/1/2009-8/31/2011
Turning the Pumpkins Pink Breast Cancer Research Award, $37,322; 11/01/2010-10/30/2011.
John Wayne Cancer Institute Maria Lim McClay Research Fund recipient, $50,000/y/5y,
2010.
Fashion Footwear Association of New York Breast Cancer Research Award (project PI),
$275,500; 05/19/2009--05/18/2011.
UCLA Clinical & Translational Science Institute Core Voucher Award (NIH the National
Center for Research Resources, UL1RR033176; the National Center for Advancing
Translational Sciences, UL1TR000124), $4,400; 12/2011--02/2012.
NIH/NCI, SBIR, HHSN261201100089C (Co-PI), $149,622; 9/15/11--6/14/12.
Current


Avon Foundation Research Award, 02-2010-068, $300,000; 7/01/2010--12/31/2013.
NIH/NCI, RO1, CA151610, $1,934,000; 2/14/2011--1/31/2016.
8

David Salomon Translational Breast Cancer Research Fund, $200,000; 7/01/2012-6/30/2014.
Pending



NIH/NCI, RO1 (CA157854)
NIH/NCI, R21 (CA173342)
Avon Foundation Research Award
9